Merck Wins Block On Teva's Generic Singulair

Law360, New York (August 19, 2009, 5:13 PM EDT) -- Merck Sharpe & Dohme Pharmaceuticals SRL has won an injunction barring Teva Pharmaceutical Industries Ltd. from making a generic version of Merck's allergy and asthma drug Singulair.

Judge Garrett E. Brown of the U.S. District Court for the District of New Jersey ruled Wednesday that Teva's proposed generic drug would violate a Merck patent covering Singulair. He ordered Teva not to make generic Singulair, and ordered the U.S. Food and Drug Administration not to approve the generic Singulair until after Merck's patent expires in 2012....
To view the full article, register now.